News & Events

16 04, 2024

Join Avance Biosciences™ at the WRIB Conference – May 6-10, 2024

2024-04-16T16:19:43+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences™ at the WRIB Conference – May 6-10, 20242024-04-16T16:19:43+00:00
3 04, 2024

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy

2024-04-03T16:11:06+00:00

CAR T-cell therapies show promise for blood cancers but struggle with solid tumors due to T-cell weakness in tumor microenvironments. Researchers find genetic alterations in cancerous T cells, giving engineered T cells "superpowers" to effectively kill tumors without behaving like cancer cells...

Stealing Strategies from Cancerous T Cells May Boost Immunotherapy2024-04-03T16:11:06+00:00
28 03, 2024

Join Avance Biosciences™ at the World Vaccine Congress – April 1st, 2024

2024-03-28T15:36:48+00:00

Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and sample testing services in support of biological drug discovery, development and manufacturing...

Join Avance Biosciences™ at the World Vaccine Congress – April 1st, 20242024-03-28T15:36:48+00:00
25 03, 2024

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

2024-03-25T14:26:50+00:00

In a groundbreaking development that could revolutionize organ transplantation, eGenesis, a biotechnology company dedicated to addressing the global organ shortage crisis, has announced the successful transplantation of a genetically engineered porcine kidney into a living human recipient...

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient2024-03-25T14:26:50+00:00
14 03, 2024

qPCR or ddPCR for Bioanalysis? – Download our Comprehensive Guide

2024-03-14T15:43:45+00:00

This comprehensive guide explores the essential tools of quantitative PCR (qPCR) and digital droplet PCR (ddPCR) in the biopharmaceutical industry, offering invaluable insights into their applications, strengths, and limitations. Download now to stay ahead of the curve in pharmaceutical research and development...

qPCR or ddPCR for Bioanalysis? – Download our Comprehensive Guide2024-03-14T15:43:45+00:00
7 03, 2024

Join Avance Biosciences™ at BioProcess International West – March 2024

2024-03-07T15:49:42+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences™ at BioProcess International West – March 20242024-03-07T15:49:42+00:00
5 03, 2024

Join Avance Biosciences™ at the SOT Annual Meeting – Mar 2024

2024-03-05T17:01:48+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Society of Toxicology Annual Meeting in Salt Lake City, and we cordially invite you to join us! More than 5,000 toxicologists and those working in areas related to toxicology will share the latest science and technology...

Join Avance Biosciences™ at the SOT Annual Meeting – Mar 20242024-03-05T17:01:48+00:00
6 02, 2024

FDA issues final guidelines on incorporating human genome editing in gene therapy products

2024-02-06T14:29:16+00:00

The guidance provides recommendations regarding information that should be provided in an investigational new drug (IND) application to assess the safety and quality of the investigational GE product, including information on product design, product manufacturing and testing, nonclinical safety...

FDA issues final guidelines on incorporating human genome editing in gene therapy products2024-02-06T14:29:16+00:00
16 01, 2024

FDA’s Innovative Approach to Global Gene Therapy Collaboration

2024-01-16T17:06:00+00:00

In a landmark move, the FDA has initiated the Collaboration on Gene Therapies Global Pilot (CoGenT), signaling a significant leap toward worldwide collaboration in the field of gene therapy. This pilot aims to enable concurrent collaborative reviews of new gene therapy applications with global regulators…

FDA’s Innovative Approach to Global Gene Therapy Collaboration2024-01-16T17:06:00+00:00
9 01, 2024

FDA issues new draft guidelines on potency assurance for cell and gene therapy products

2024-01-09T14:31:40+00:00

In this draft guidance, the FDA emphasizes that potency assays and their corresponding acceptance criteria should be designed to make meaningful contributions to potency assurance by reducing risks to product potency. They provide illustrative examples of approaches to potency assay development that are...

FDA issues new draft guidelines on potency assurance for cell and gene therapy products2024-01-09T14:31:40+00:00